DataMeds AI, Inc. (NASDAQ: MEDS) licensed exclusive US D2C rights to REBOOT Health AI's GLP-1 care-management platform (announced 14 Oct 2026) for integration into its Health Lives Here app as a subscription offering. Claims six patents and six pending around data-driven outcome optimization.
US consumers on GLP-1 medications (intended app subscribers); NFL Alumni Health partnership named as marketing channel.
Monthly subscription basis announced; amounts not published.
Vertically integrated model: Health Lives Here app, Corexa Health pharmacy/distribution (licensed to dispense FDA-approved GLP-1s), Helomics CLIA lab, Tollo Health nutraceuticals. Patients may choose their own pharmacy.
Corexa Health pharmacy and distribution divisions (company-owned); patient-choice pharmacy also supported.
No attributable ads found in Google, Meta or LinkedIn public libraries on 20 Oct 2026; LinkedIn fuzzy matches are name collisions. See dated channel evidence.
REBOOT platform developed over ten years; Data Health Partners founded early 2022; license announced 14 Oct 2026.
Interim co-CEO Gerald E. Commissiong (also leads Tollo Health); REBOOT CEO Paul Arena. Data Health Partners described as founded by serial entrepreneurs, unnamed in the release.
Tampa, FL (release dateline); Helomics lab in Pittsburgh.
Not assessed in this pass.